Navigation Links
Chimerix Raises $16.1 Million in Series E Financing
Date:8/11/2009

RESEARCH TRIANGLE PARK, N.C., Aug. 11 /PRNewswire/ -- Chimerix, Inc., a biotechnology company developing orally available antiviral therapeutics, today announced the completion of a $16.1 million Series E financing. Leading life science venture capital investors Canaan Partners, Alta Partners, Sanderling Ventures and Asset Management Company participated in this insider round.

Proceeds from the financing will primarily be used to expand Chimerix's clinical development program for its lead drug candidate, CMX001. CMX001 has shown activity in early clinical studies as a broad-spectrum antiviral drug, and is currently being evaluated for the treatment of cytomegalovirus (CMV) and BK virus in Phase II clinical trials. CMX001 is also being developed as a biodefense agent for the treatment of smallpox and complications associated with smallpox vaccination. In addition, Chimerix expects to advance CMX157, an anti-HIV drug, into Phase I clinical development and to continue work on a library of compounds that have shown extremely potent activity against a range of viral diseases including hepatitis C.

"Chimerix's robust pharmaceutical product pipeline and world-class expertise in the area of antiviral medicines offer truly novel and promising approaches for the treatment of a number of challenging viral and inflammatory diseases," said Seth Rudnick, M.D., of Canaan Partners and Co-Chairman of the company's Board of Directors. "We believe that this financing will enable the Chimerix team to continue doing what they do best - identify, optimize and develop important new antiviral medicines that address significant therapeutic markets and may prove valuable in our nation's biodefense strategy."

"We are pleased by the consistent support Chimerix has received from such a premier group of experienced life science investors," said George Painter, Ph.D., Chimerix's President and Chief Execut
'/>"/>

SOURCE Chimerix, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Ex-House Aging Committee Chief of Staff Bob Weiner Warns of Insurance Control Over Health Bill Outcome, Praises House Version, Disappointed by Senate; Weiner and Policy Analyst Jordan Osserman Offer Bills Prognosis
2. High cholesterol in midlife raises risk of late-life dementia, Kaiser Permanente study finds
3. High Cholesterol in Midlife Raises Risk of Late-Life Dementia, Kaiser Permanente Study Finds
4. HMS Holdings Corp. Announces Q2 2009 Results and Raises 2009 Guidance
5. Watson Pharmaceuticals Reports Second Quarter 2009 GAAP EPS of $0.46; Adjusted EPS $0.61; Company Raises 2009 Outlook
6. Be a Hero For Babies Day Raises $2.6 Million for March of Dimes
7. Hanger Orthopedic Group, Inc. Reports $0.31 EPS for the Second Quarter 2009 and Raises Full Year EPS Guidance
8. Universal Health Services, Inc. Reports Significant Increases In 2009 Second Quarter and Six-Month Earnings, Raises Full Year Guidance
9. aTyr Pharma Raises an Additional $12 Million
10. Applied Physiology Raises $5 Million for Navigator™ Market Launch
11. Wyeth Reports Earnings Results for the 2009 Second Quarter and First Half and Raises Full Year 2009 Guidance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/3/2015)... ... September 03, 2015 , ... Global Vision , the world leader in ... its award-winning print and artwork inspection solutions, ScanProof and ArtProof at Packaging ... the Olympia London, booth #F33 , Be the first to get a sneak peek ...
(Date:9/3/2015)... ... September 03, 2015 , ... DiabetesSisters ... pleased to announce the additional of Carol Wysham, MD, to their esteemed Board ... Diana Karczmarczyk, Donna Rice, David Warren, Matt Stella, Tricia Cedotal, Andrea Thomas, Wanda ...
(Date:9/3/2015)... ... ... ProScrub is a set of automated tools that allow Final Cut Pro ... without the use of keyframes. Utilize ProScrub's powerful sliders to determine the number ... to energetic video productions. ProScrub is a Final Cut Pro X ...
(Date:9/3/2015)... Jersey City, NJ (PRWEB) , ... September 03, 2015 , ... ... devices, announced today that AvePoint Perimeter Service Pack (SP) 4 – AvePoint’s ... – has been named a “KMWorld 2015 Trend-Setting Product”. This is the ...
(Date:9/3/2015)... ... 03, 2015 , ... Representatives with State Farm Agent EJ ... Mississippi Gulf Babypalooza on September 19, 2015. , “We will be providing information ... beyond. We will be discussing setting up college funds, offering information specific to ...
Breaking Medicine News(10 mins):Health News:Global Vision to Spotlight Intelligent Proofreading at Packaging Innovations 2015 2Health News:Global Vision to Spotlight Intelligent Proofreading at Packaging Innovations 2015 3Health News:Carol H. Wysham, MD, Joins DiabetesSisters Board of Directors 2Health News:FCPX Effects Developer Releases ProScrub for Final Cut Pro X 2Health News:AvePoint Perimeter Named a “KMWorld 2015 Trend-Setting Product” 2Health News:AvePoint Perimeter Named a “KMWorld 2015 Trend-Setting Product” 3Health News:AvePoint Perimeter Named a “KMWorld 2015 Trend-Setting Product” 4Health News:State Farm Agent EJ Roberts to Help Expecting Mothers at the Mississippi Gulf Babypalooza 2
... mass, but long-term effects on vitality unclear, scientists say ... experimental drug can restore the amounts of muscle-linked growth ... shows. , Those on the therapy also gained muscle ... no clear indication that this led to significant improvements ...
... percent versus third quarter last year ... 4:30 p.m. Eastern Time Today, IRVINE, Calif., Nov. 6 ... intravascular temperature,management (IVTM(TM)) therapies for critically ill patients, today reported,on ... and,nine months ended September 30, 2008., Revenue for the ...
... Company Delivers First Month of Positive Gross Profits ... Corporation,(Nasdaq: PODD ), the leader in patch pump ... results for the three,and nine months ended September 30, ... $10.1 million compared to,$3.8 million in the third quarter ...
... November 06, 2008 Down syndrome, the most ... 1-in-700 births in the United States. Additionally, nearly 80 ... birth. , The Centers for Disease Control (CDC), in ... meeting of experts to review the current knowledge of ...
... STEWARTVILLE, Minn., Nov. 6 Rochester Medical,Corporation (Nasdaq: ... and year ended September 30, 2008., The Company ... to $8,437,000 for the fourth quarter of last year. ... $.03 per diluted share,compared to $733,000 or $.06 per ...
... ... Expectations, DENVER, Nov. 6 Air Methods ... 2008.,Revenue increased 32% to $133.8 million from $101.5 million in the year-ago,quarter. ... million in the prior-year nine-month period., For the quarter, net income ...
Cached Medicine News:Health News:Drug Boosts Natural Growth Hormone in Seniors 2Health News:Drug Boosts Natural Growth Hormone in Seniors 3Health News:Drug Boosts Natural Growth Hormone in Seniors 4Health News:Alsius Corporation Reports Record Third Quarter 2008 Financial Results and Business Progress 2Health News:Alsius Corporation Reports Record Third Quarter 2008 Financial Results and Business Progress 3Health News:Alsius Corporation Reports Record Third Quarter 2008 Financial Results and Business Progress 4Health News:Alsius Corporation Reports Record Third Quarter 2008 Financial Results and Business Progress 5Health News:Alsius Corporation Reports Record Third Quarter 2008 Financial Results and Business Progress 6Health News:Alsius Corporation Reports Record Third Quarter 2008 Financial Results and Business Progress 7Health News:Insulet Reports Third Quarter 2008 Results 2Health News:Insulet Reports Third Quarter 2008 Results 3Health News:Insulet Reports Third Quarter 2008 Results 4Health News:Insulet Reports Third Quarter 2008 Results 5Health News:Insulet Reports Third Quarter 2008 Results 6Health News:Insulet Reports Third Quarter 2008 Results 7Health News:Insulet Reports Third Quarter 2008 Results 8Health News:Rochester Medical Reports Record Fourth Quarter Sales and Record Annual Sales 2Health News:Rochester Medical Reports Record Fourth Quarter Sales and Record Annual Sales 3Health News:Rochester Medical Reports Record Fourth Quarter Sales and Record Annual Sales 4Health News:Rochester Medical Reports Record Fourth Quarter Sales and Record Annual Sales 5Health News:Rochester Medical Reports Record Fourth Quarter Sales and Record Annual Sales 6Health News:Rochester Medical Reports Record Fourth Quarter Sales and Record Annual Sales 7Health News:Rochester Medical Reports Record Fourth Quarter Sales and Record Annual Sales 8Health News:Air Methods Reports 3Q2008 Results and 4Q2008 Update 2Health News:Air Methods Reports 3Q2008 Results and 4Q2008 Update 3Health News:Air Methods Reports 3Q2008 Results and 4Q2008 Update 4Health News:Air Methods Reports 3Q2008 Results and 4Q2008 Update 5Health News:Air Methods Reports 3Q2008 Results and 4Q2008 Update 6Health News:Air Methods Reports 3Q2008 Results and 4Q2008 Update 7
(Date:9/2/2015)... THOUSAND OAKS, Calif. , Sept. 2, 2015 ... announced the submission of a Marketing Authorization Application ... the centralized procedure for etelcalcetide (formerly AMG 416) ... adult patients with chronic kidney disease (CKD) on ... first calcimimetic agent that can be administered intravenously. ...
(Date:9/2/2015)... Miss. , Sept. 2, 2015   Gulf Coast Tattoo ... removal services with the cutting-edge Astanza Duality laser in ... unwanted ink erase their tattoo regret and take back control of ... but extends its services to Biloxi ... region. "With tattoo regret being as prevalent as it ...
(Date:9/2/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/6mlrvg/an_introduction ... "An Introduction to Medical Device Software: Regulations and ... conference to their offering. This ... regulations and requirements that apply to Medical Device ... real life examples and state-of- the-art practices identified ...
Breaking Medicine Technology:Amgen Submits Marketing Authorization Application For Novel Intravenous Calcimimetic Etelcalcetide (AMG 416) To The European Medicines Agency 2Amgen Submits Marketing Authorization Application For Novel Intravenous Calcimimetic Etelcalcetide (AMG 416) To The European Medicines Agency 3Amgen Submits Marketing Authorization Application For Novel Intravenous Calcimimetic Etelcalcetide (AMG 416) To The European Medicines Agency 4Amgen Submits Marketing Authorization Application For Novel Intravenous Calcimimetic Etelcalcetide (AMG 416) To The European Medicines Agency 5Amgen Submits Marketing Authorization Application For Novel Intravenous Calcimimetic Etelcalcetide (AMG 416) To The European Medicines Agency 6Amgen Submits Marketing Authorization Application For Novel Intravenous Calcimimetic Etelcalcetide (AMG 416) To The European Medicines Agency 7Gulf Coast Tattoo Removal Delivers Unrivaled Tattoo Removal Results To Biloxi And Gulfport With Astanza Duality 2An Introduction to Medical Device Software: Regulations and Requirements Course - London, UK - November 2-3, 2015 2
... and CAMPBELL, Calif. , May ... sophisticated risk characterization and personalized therapy guidelines for ... of advanced tests, offering an accompanying nutrition program, ... Director stated:  "With appropriate risk characterization and treatment, ...
... May 25 The U.S. Food and Drug Administration approved Lumizyme (alglucosidase ... a rare genetic disorder. , , ... http://www.newscom.com/cgi-bin/prnh/20090824/FDALOGO ) , , , ... an estimated 1 in every 40,000 to 300,000 births. Its primary symptom is ...
Cached Medicine Technology:Health Network Laboratories (HNL) Enters Into License Agreement With Hunter Laboratories to Provide HunterHeart Cardiovascular Disease Management Program. 2FDA Approves New Treatment for Late-Onset Pompe Disease 2FDA Approves New Treatment for Late-Onset Pompe Disease 3
... flexible lighting products. The first is available ... sizes 5", 10", and 15" (refers to ... These lights are for use in procedures ... second group of flexible lights is our ...
These units, though small, still offer sufficient output to ensure current is fully adjustable from 0 to 70 mA. Instruction manual, ball electrodes, battery and leads with alligator clips are include...
These units, though small, still offer sufficient output to ensure current is fully adjustable from 0 to 70 mA. Instruction manual, ball electrodes, battery and leads with alligator clips are include...
... standby switch maintains power to the instrument without generating ... of 50 Hz separated by .75 s; repeats every ... Hz (2 pulses/s) , Tetanus: 50 Hz (50 ... pulses/2 s; repeats every 10 s , Output Current: ...
Medicine Products: